The alliance was initiated in October 2005 and is focused on the discovery, development, and commercialization of RNAi therapeutics toward a defined number of Novartis-selected disease gene targets.
Under the terms of the agreement, Smiths Medical will provide its Medfusion Syringe Infusion System and CADD Ambulatory Infusion Systems to HealthTrust’s over 1,400 acute care hospitals and
The license grants Medarex non-exclusive rights to research, develop and commercialize therapeutic antibodies based on Complegent technology for an undisclosed number of targets. In return, BioWa will receive
MediGene therefore acquires an exclusive worldwide license for the application and commercialization of Anti L1 antibodies in anti-tumor therapy. In June 2006, MediGene and the German Cancer Research
Under the terms of the settlement, Wyeth has granted Impax a license that would permit Impax to launch its capsule formulation of Effexor XR on or after June
BioMarin will receive a milestone payment of $1.5 million for this marketing approval along with double-digit royalties on net sales of Biopten for phenylketonuria (PKU) in Japan under
The Attract-2 trial will be conducted by Antisoma’s partner, Novartis, and will evaluate ASA404 as a second-line treatment for non-small cell lung cancer (NSCLC). A separate, ongoing phase
Sciele Pharma is working closely with Summers Laboratories and the FDA to provide additional information that was requested.
According to the company, HEK293 cells are the most widely used human cell line in biotechnology industry and the only human cell line used for the bioproduction of
Following recent acquisitions in Croatia and Romania, the purchase of Armila is said to represent the latest stage in Anzag’s strategy to establish itself in carefully targeted high-growth
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.